Dr. Justine Badée is a distinguished pharmacokinetics researcher with over eight years of experience in the pharmaceutical industry, primarily focusing on physiologically-based pharmacokinetic (PBPK) modeling. Currently serving as a Principal Scientist II at Novartis in Basel, Switzerland, she leads modeling efforts to support drug development from First-in-Human studies to regulatory submissions. Dr. Badée holds a Ph.D. in Pharmacokinetics and Drug Metabolism from the University of Manchester and has a strong foundation as a pharmacist and researcher. Her work encompasses a wide range of applications including drug-drug interactions, pediatric dosing, lactation modeling, and biopharmaceutic assessments. In addition to her scientific contributions, she has mentored Ph.D. students, driven external collaborations with international organizations such as Simcyp and the IQ Consortium, and delivered presentations at leading global conferences. Her multi-disciplinary approach and applied modeling expertise have led to significant advancements in PBPK methodologies and their regulatory application. Dr. Badée has authored and co-authored numerous scientific publications and contributed actively to the development of industry best practices in pharmacokinetics. She is recognized not only for her technical excellence but also for her leadership, mentoring, and collaborative spirit, making her a key contributor to the field of clinical pharmacology and drug metabolism.

Professional Profile

• Scopus Profile

Education

Justine Badée possesses a comprehensive and rigorous academic background in pharmacokinetics and pharmaceutical sciences. She completed her Ph.D. in Pharmacokinetics and Drug Metabolism at the Centre for Applied Pharmacokinetic Research (CAPkR), University of Manchester, UK, where she focused on hepatic uptake clearance and its in vitro to in vivo translation. Her research was supported by joint funding from AstraZeneca and the UK Biotechnology and Biological Sciences Research Council. Prior to her doctoral studies, she earned a Master’s degree in Pharmacokinetics from the Faculty of Pharmacy at University René Descartes V in Paris, France. Additionally, she holds a pharmacy degree from the same institution, completing her training as a licensed pharmacist. Her academic foundation was further strengthened by a scientific high school diploma with a physics major from Saint-Erembert High School in France. Dr. Badée’s academic journey has not only equipped her with a solid theoretical and experimental knowledge base but also cultivated a robust understanding of pharmacological principles and translational research. Her diverse educational pathway—spanning pharmaceutical sciences, clinical pharmacokinetics, and drug metabolism—has played a critical role in her ability to engage in complex modeling tasks and collaborative international research efforts in drug development.

Professional Experience

Dr. Justine Badée’s professional experience reflects a dynamic and upward trajectory in the pharmaceutical and academic sectors. Since 2019, she has been a Clinical PBPK Modeler and Principal Scientist II at Novartis in Basel, where she applies PBPK modeling to a range of clinical drug development scenarios, including DDI predictions, population-specific dosing, and regulatory submissions. She also completed a three-month managerial rotation as a Project Team Manager in oncology, supporting protocol design and pharmacokinetic analysis. Her prior postdoctoral work was jointly conducted at the Center for Pharmacometrics and Systems Pharmacology, University of Florida, and at Hoffmann-La Roche, where she advanced pediatric dose selection by investigating UGT enzyme ontogeny. As a Ph.D. student at the University of Manchester, she led projects on hepatic uptake clearance and nonlinear mixed-effects modeling. Earlier in her career, she held internships at Novartis and INSERM and served as an extern pharmacist at Beaujon Hospital in Paris. Across roles, she has integrated bench research, computational modeling, and clinical applications, resulting in a comprehensive skill set. Her trajectory from laboratory-based research to high-level modeling in an industrial setting exemplifies her adaptability, technical expertise, and commitment to translating pharmacokinetic theory into practice.

Research Interests

Dr. Badée’s research interests lie at the intersection of pharmacokinetics, drug metabolism, and translational modeling. A key focus of her work is the development and application of physiologically-based pharmacokinetic (PBPK) models to optimize drug dosing, predict drug-drug interactions, and inform regulatory decisions. She is particularly interested in special populations—pediatrics, lactating women, and patients with hepatic or renal impairment—where traditional pharmacokinetic approaches often fall short. Her research extends into enzyme ontogeny, especially hepatic UGT isoforms, and how their developmental profiles affect drug metabolism across life stages. Dr. Badée is also engaged in refining in vitro methodologies to better predict in vivo drug behavior, with a focus on improving the reliability of automated glucuronidation assays. Her interest in translational research is evident through her active involvement in industry consortia and collaborative initiatives aimed at improving PBPK workflows and regulatory confidence. Furthermore, she explores innovative model-based approaches to address complex drug development challenges, such as enzyme induction and transporter-mediated drug disposition. Through these pursuits, she contributes to bridging gaps between laboratory findings, clinical implementation, and regulatory science, demonstrating a keen interest in both theoretical development and real-world application of pharmacokinetic modeling.

Research Skills

Dr. Justine Badée possesses a robust portfolio of research skills spanning pharmacokinetic modeling, laboratory techniques, and collaborative project execution. Her core technical competencies include physiologically-based pharmacokinetic (PBPK) modeling using tools such as Simcyp, GastroPlus, and PK-Sim, as well as nonlinear mixed-effect (NLME) modeling with NONMEM. She is adept at both population pharmacokinetics and PK/PD modeling, utilizing software such as WinNonlin/Phoenix, GraphPad Prism, and R. In laboratory settings, she has conducted molecular biology experiments, bioanalytical quantification using LC-MS/MS, protein assays, and hepatocyte isolation, among others. Her experience includes designing and optimizing in vitro uptake and glucuronidation assays to model hepatic metabolism accurately. Dr. Badée’s skills extend beyond the bench and computational tasks—she is also a skilled scientific communicator and collaborator. She has mentored Ph.D. students, led cross-functional teams, and actively participated in international scientific workshops and training programs. Her ability to integrate laboratory findings into advanced modeling platforms reflects her interdisciplinary expertise. Collectively, these skills position her as a valuable contributor to both the academic and industry research ecosystems, ensuring she can translate complex scientific questions into actionable insights for drug development and regulatory strategy.

Awards and Honors

Throughout her career, Dr. Justine Badée has received multiple prestigious awards and recognitions for her scientific excellence and research impact. These include the IQ Recognition Award (2021), the American College of Clinical Pharmacology (ACCP) Wayne A. Colburn Memorial Award (2018), and the ACCP Student Award. Her poster presentations have consistently garnered top honors, winning first-place awards at the Drug Metabolism Discussion Group (DMDG) and Group of Metabolism and Pharmacokinetics (GMP) meetings in 2013 and 2014. In 2023, she received a poster award at the Marbach Drug-Drug Interaction Workshop, further underscoring her contributions to advancing PBPK modeling. In addition to these accolades, she received a certificate of outstanding reviewer for the European Journal of Pharmaceutical Sciences in 2018, recognizing her critical evaluation and contribution to scientific literature. These awards reflect both the scientific rigor and practical relevance of her research. Her consistent recognition by professional bodies and conference committees highlights her leadership in modeling-based drug development and her commitment to excellence in pharmacological science. Dr. Badée’s accolades not only mark her individual achievements but also affirm her role in shaping current and future best practices in pharmacokinetic research.

Conclusion

In conclusion, Dr. Justine Badée represents a rare combination of scientific depth, practical impact, and collaborative leadership in the field of pharmacokinetics. Her contributions span the full spectrum of drug development—from mechanistic in vitro studies to sophisticated PBPK modeling and regulatory submissions. She has successfully bridged academia and industry, delivering actionable solutions to complex pharmacokinetic challenges. Her numerous peer-reviewed publications, awards, and leadership in international collaborations reflect a researcher deeply engaged in advancing the field and mentoring the next generation. With her ability to innovate, communicate, and translate science into therapeutic outcomes, Dr. Badée has established herself as a leading figure in modeling and simulation. Her work not only informs clinical and regulatory decisions but also contributes to safer and more effective drug use in vulnerable populations. As she continues to build on this strong foundation, her career promises further innovations in model-informed drug development. Dr. Badée is an ideal candidate for recognition through the Best Researcher Award, and her work exemplifies the highest standards of scientific inquiry and professional dedication.

Publications Top Notes

• Predicting Drug Transfer into Human Milk with the Simcyp Simulator: A contribution from the ConcePTION Project
  Macente J, Nauwelaerts N, Badée J, Huang MC, Hernandes Bonan R, Van Neste M, Smits A, Allegaert K, Severino Martins F, Annaert P.
  2025

• Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective
  Reddy MB, Cabalu TD, de Zwart L, Ramsden D, Dowty ME, Taskar KS, Badée J, Bolleddula J, Boulu L, Fu Q, Kotsuma M, Leblanc AF, Lewis G, Liang G, Parrott N, Pilla Reddy V, Prakash C, Shah K, Umehara K, Mupkherjee D, Rehmel J, Hariparsad N.
  2025

• Generic workflow to predict medicine concentrations in human milk using physiologically-based pharmacokinetic (PBPK) modelling – A contribution from the concePTION project
  Nauwelaerts N, Macente J, Hernandes Bonan R, Huang MC, Van Neste M, Bibi D, Badée J, Martins FS, Smiths A, Allegaert K, Bouillon T, Annaert P.
  2023

• Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective
  Hariparsad N, Ramsden D, Taskar K, Badée J, Venkatakrishnan K, Reddy MB, Cabalu T, Mukherjee D, Rehmel J, Bolleddula J, Emani Riedmaier A, Prakash C, Chanteux H, Mao J, Umehara K, Shah K, De Zwart L, Dowty M, Kotsuma M, Li M, Pilla Reddy V, McGinnity DF, Parrott N.
  2021

• Characterization of Hepatic UDP-Glucuronosyl Transferase Enzymes Abundance – Activity Correlations and Population Variability using a Proteomics Approach and Comparison with Cytochrome P450 Enzymes
  Takahashi RH, Forrest W, Smith AD, Badée J, Qiu N, Schmidt S, Collier CA, Parrott N, Fowler S.
  2021

• Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species
  van Groen BD, Nicolaï J, Kuik AC, van Cruchten S, van Peer E, Schmidt S, de Wildt SN, Allegaert K, de Schaepdrijver L, Annaert P, Badée J.
  2021

• Paediatric pharmacokinetics and dose predictions: a report of a satellite meeting to the 10th Juvenile Toxicity Symposium
  van Groen BD, Pilla Reddy V, Badée J, Olivares-Morales A, Johnson TN, Nicolaï J, Annaert P, Smits A, de Wildt SN, Knibbe CAJ, de Zwart L.
  2021

• Co-expression of human hepatic uridine diphosphate glucuronosyltransferase (UGT) proteins: Implications for ontogenetic mechanisms and isoform co-regulation
  Liu Y, Badée J, Takahashi RH, Schmidt S, Parrott N, Fowler S, Mackenzie PI, Coughtrie MWH, Collier AC.
  2020

• Use of Phenotypically Poor Metaboliser Individual Donor Human Liver Microsomes to Identify Selective Substrates of UGT2B10
  Milani N, Qiu N, Molitor B, Badée J, Cruciani G, Fowler S.
  2020

• Characterization of the Ontogeny of Hepatic UDP-Glucuronosyl Transferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes
  Badée J, Qiu N, Collier CA, Takahashi RH, Forrest W, Parrott N, Schmidt S, Fowler S.
  2019